title: Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.
abstract: BACKGROUND
  The MERIT study evaluated maraviroc versus efavirenz, both with zidovudine/lamivudine, in treatment-naïve patients with CCR5-tropic (R5) HIV-1. Post hoc analyses previously assessed week 48 outcomes in patients rescreened with R5 virus by a more sensitive tropism assay.
  
  
  METHODS
  Week 96 efficacy (post hoc, n = 614) and safety (n = 721) were assessed.
  
  
  RESULTS
  Proportions of subjects <50 copies/mL (58.8% maraviroc, 62.7% efavirenz) and time to loss of virologic response (TLOVR) responders (<50 copies/mL: 60.5% vs 60.7%) were similar. Maraviroc recipients had greater CD4 increases (+ 212 vs + 171 cells/mm(3)) and fewer adverse event discontinuations (6.1% vs 15.5%), malignancies, and category C events.
  
  
  CONCLUSIONS
  Week 96 data confirm week 48 observations in MERIT.
authors.affiliation: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CIFBIOTEC Medica Sur, Tlalpan, Mexico.
authors.forename: Juan
authors.initials: J
authors.lastname: Sierra-Madero
authors.forename: Giovanni
authors.initials: G
authors.lastname: Di Perri
authors.forename: Robin
authors.initials: R
authors.lastname: Wood
authors.forename: Michael
authors.initials: M
authors.lastname: Saag
authors.forename: Ian
authors.initials: I
authors.lastname: Frank
authors.forename: Charles
authors.initials: C
authors.lastname: Craig
authors.forename: Robert
authors.initials: R
authors.lastname: Burnside
authors.forename: Jennifer
authors.initials: J
authors.lastname: McCracken
authors.forename: Dennis
authors.initials: D
authors.lastname: Pontani
authors.forename: James
authors.initials: J
authors.lastname: Goodrich
authors.forename: Jayvant
authors.initials: J
authors.lastname: Heera
authors.forename: Howard
authors.initials: H
authors.lastname: Mayer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D048588:Benzoxazines / Q000009:adverse effects / Q000627:therapeutic use*; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use*; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D005260:Female; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D003521:Cyclopropanes; D023581:HIV Fusion Inhibitors; D014230:Triazoles; D019259:Lamivudine; D015215:Zidovudine; C098320:efavirenz; D000077592:Maraviroc